Moreover, this regimen is associated with well-recognized risks—including secondary hyperparathyroidism, nephrocalcinosis, and gastrointestinal intolerance—and does not address the underlying FGF23-mediated disease mechanism [6]. This evidence concerns the gene FGF23 and secondary hyperparathyroidism.